SpectraCure: Preliminary results from SpectraCures prostate treatments
Preliminary results have been reported from the latest patient
treatments in SpectraCures clinical trial for the treatment of
patients with recurrent prostate cancer, at University College London
Hospital. A very clear treatment effect is seen on MR images in the
treatment area, indicating destruction of the tumour, just like
previously treated patients with the high drug dose.
In the patients where follow-up of PSA values has been made, very
clear reduction of PSA is seen after treatment, with decreases in the
range of 50-73%.
It is very gratifying that we get continued good results, says
Johannes Swartling, CTO. We are also pleased with the good
cooperation with the team in London and we look forward to the
continuation of the study.
The purpose of SpectraCures Phase 2 study is to show that the method
is safe to use, and that it has clinical effect, with a larger
statistic basis than in the Phase 1 study.
For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: email@example.com,
phone: +46(0) 8 503 000 50
This information is information that SpectraCure AB is required to
disclose under the EU Market Abuse Regulation. The information was
provided, through the contact of the above contact person, for
publication on May 23th, 2019.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University
departments for medical laser applications and physics. The company
focuses on cancer treatments using medical systems with laser light
sources and reactive drugs, which is referred to as Interstitial
Photodynamic Therapy, PDT, a treatment methodology suitable for
internal solid tumours of various kind, e.g. prostate and abdominal
salivary glands, but also other indications such as cancer tumours in
the head and neck region